Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database ; volume:13 ; number:1 ; day:8 ; month:12 ; year:2023 ; pages:1-7 ; date:12.2023
Blood cancer journal ; 13, Heft 1 (8.12.2023), 1-7, 12.2023
- Creator
-
Visram, A.
De La Torre, A.
White, D.
Su, J.
Masih-Khan, E.
Chu, M.
Jimenez-Zepeda, V.
McCurdy, A.
LeBlanc, R.
Song, K.
Mian, H.
Louzada, M.
Sebag, M.
Bergstrom, D.
Stakiw, J.
Reiman, A.
Kotb, R.
Aslam, M.
Venner, C.
Kaedbey, R.
Gul, E.
Reece, D.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-023-00946-z
- URN
-
urn:nbn:de:101:1-2024022609390081883017
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Visram, A.
- De La Torre, A.
- White, D.
- Su, J.
- Masih-Khan, E.
- Chu, M.
- Jimenez-Zepeda, V.
- McCurdy, A.
- LeBlanc, R.
- Song, K.
- Mian, H.
- Louzada, M.
- Sebag, M.
- Bergstrom, D.
- Stakiw, J.
- Reiman, A.
- Kotb, R.
- Aslam, M.
- Venner, C.
- Kaedbey, R.
- Gul, E.
- Reece, D.
- SpringerLink (Online service)
Other Objects (12)
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Sorafenib in patients with refractory or recurrent multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Sorafenib in patients with refractory or recurrent multiple myeloma
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Sorafenib in patients with refractory or recurrent multiple myeloma